Status:
COMPLETED
[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions:
Colorectal Cancer Control and Prevention
Colorectal Cancer Recurrent
Eligibility:
All Genders
Phase:
NA
Brief Summary
This diagnostic study investigates the value of 68Ga-NOTA-GZP PET imaging in predicting and evaluating immunotherapy response in malignant tumors by enrolling pathologically confirmed patients schedul...
Detailed Description
Malignant tumors represent one of the leading causes of mortality worldwide, posing a significant threat to human health, where early diagnosis and timely intervention can substantially improve clinic...
Eligibility Criteria
Inclusion
- Histologically confirmed treatment-naïve locally advanced rectal adenocarcinoma (T3-4N0M0 or T1-4N+M0)
- No severe hematologic, cardiac, pulmonary, hepatic, or renal dysfunction
- No immunodeficiency diseases
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Exclusion
- Prior anti-PD-1/PD-L1 antibody therapy
- History of pelvic radiotherapy
- Active autoimmune disease (excluding vitiligo and type 1 diabetes)
- Hypersensitivity to monoclonal antibodies
- History of interstitial lung disease
- Active uncontrolled infection
Key Trial Info
Start Date :
May 6 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2025
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT06982053
Start Date
May 6 2024
End Date
March 31 2025
Last Update
May 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Wuhan, China, 430000